Cargando…

Potential immunological consequences of pharmacological suppression of gastric acid production in patients with multiple sclerosis

Corticosteroids are standard treatment for patients with multiple sclerosis experiencing acute relapse. Because dyspeptic pain is a common side effect of this intervention, patients can be given a histamine receptor-2 antagonist, proton pump inhibitor or antacid to prevent or ameliorate this disturb...

Descripción completa

Detalles Bibliográficos
Autores principales:	Biswas, Sangita, Benedict, Stephen H, Lynch, Sharon G, LeVine, Steven M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3386885/ https://www.ncbi.nlm.nih.gov/pubmed/22676575 http://dx.doi.org/10.1186/1741-7015-10-57

Ejemplares similares

Iron chelation and multiple sclerosis
por: Weigel, Kelsey J., et al.
Publicado: (2014)

Aspirin and multiple sclerosis
por: Tsau, Sheila, et al.
Publicado: (2015)

Albumin and multiple sclerosis
por: LeVine, Steven M.
Publicado: (2016)

Is There an Increased Risk for Ischemic Stroke in Patients with Multiple Sclerosis, and If So, Should Preventive Treatment Be Considered?
por: LeVine, Steven M.
Publicado: (2016)

Iron deposition is independent of cellular inflammation in a cerebral model of multiple sclerosis
por: Williams, Rachel, et al.
Publicado: (2011)

Metabolic pathways as possible therapeutic targets for progressive multiple sclerosis
por: Heidker, Rebecca M., et al.
Publicado: (2017)

Immunological and clinical consequences of splenectomy in a multiple sclerosis patient treated with natalizumab
por: Lee, De-Hyung, et al.
Publicado: (2013)

Multiple sclerosis
por: Lynch, Sharon G., et al.
Publicado: (1996)

Multiple sclerosis: Possible immunological mechanisms()
por: McFarland, Henry F., et al.
Publicado: (1989)

Immunological role of sulfatide in the pathogenesis of multiple sclerosis
por: Hamatani, Mio, et al.
Publicado: (2023)

Ferroptosis contributes to multiple sclerosis and its pharmacological targeting suppresses experimental disease progression
por: Van San, Emily, et al.
Publicado: (2023)

Mesenchymal Stem Cells and Induced Pluripotent Stem Cells as Therapies for Multiple Sclerosis
por: Xiao, Juan, et al.
Publicado: (2015)

Determinants of Disability in Multiple Sclerosis: An Immunological and MRI Study
por: Tortorella, Paola, et al.
Publicado: (2014)

CTLA4 as Immunological Checkpoint in the Development of Multiple Sclerosis
por: Gerdes, Lisa Ann, et al.
Publicado: (2016)

Pharmacological and Non-pharmacological Therapies of Cognitive Impairment in Multiple Sclerosis
por: Miller, Elżbieta, et al.
Publicado: (2018)

Long-term immunological consequences of anti-CD20 therapies on humoral responses to COVID-19 vaccines in multiple sclerosis: an observational study
por: Moser, Tobias, et al.
Publicado: (2022)

Examining the Role of a Functional Deficiency of Iron in Lysosomal Storage Disorders with Translational Relevance to Alzheimer’s Disease
por: LeVine, Steven M.
Publicado: (2023)

Compositionally and functionally distinct sinus microbiota in chronic rhinosinusitis patients have immunological and clinically divergent consequences
por: Cope, Emily K., et al.
Publicado: (2017)

Diagnostic delay of multiple sclerosis: prevalence, determinants and consequences
por: Uher, Tomas, et al.
Publicado: (2023)

Types of immunological failure in the "slow-virus" encephalopathies and multiple sclerosis.
por: Booss, J.
Publicado: (1980)

Immunology and Oxidative Stress in Multiple Sclerosis: Clinical and Basic Approach
por: Ortiz, Genaro G., et al.
Publicado: (2013)

Clinical Immunological Correlations in Patients with Multiple Sclerosis Treated with Natalizumab
por: Maier, Smaranda, et al.
Publicado: (2020)

Infectious and immunologic consequences of blood transfusion
por: Dellinger, E Patchen, et al.
Publicado: (2004)

Immunological consequences of kidney cell death
por: Sarhan, Maysa, et al.
Publicado: (2018)

On the Immunological Consequences of Conventionally Fractionated Radiotherapy
por: Alfonso, Juan Carlos L., et al.
Publicado: (2020)

Immunological consequences of microbiome-based therapeutics
por: Alam, Md Zahidul, et al.
Publicado: (2023)

Inflammation and Oxidative Stress in Multiple Sclerosis: Consequences for Therapy Development
por: Pegoretti, Valentina, et al.
Publicado: (2020)

Engineered immunological niches to monitor disease activity and treatment efficacy in relapsing multiple sclerosis
por: Morris, Aaron H., et al.
Publicado: (2020)

Ocrelizumab for the Treatment of Multiple Sclerosis: Safety, Efficacy, and Pharmacology
por: Mancinelli, Chiara Rosa, et al.
Publicado: (2021)

An Overview of the History, Pathophysiology, and Pharmacological Interventions of Multiple Sclerosis
por: Dighriri, Ibrahim M, et al.
Publicado: (2023)

Role of Immunological Memory Cells as a Therapeutic Target in Multiple Sclerosis
por: Bose, Tanima
Publicado: (2017)

Immunological Subsets Characterization in Newly Diagnosed Relapsing–Remitting Multiple Sclerosis
por: D’Amico, Emanuele, et al.
Publicado: (2022)

Substrate Reduction Therapy for Krabbe Disease: Exploring the Repurposing of the Antibiotic D-Cycloserine
por: LeVine, Steven M., et al.
Publicado: (2022)

Multiple sclerosis /
por: Warren, Sharon
Publicado: (2001)

The IUPHAR Guide to Immunopharmacology: connecting immunology and pharmacology
por: Harding, Simon D., et al.
Publicado: (2020)

The relationship between fatigability and sleep quality in people with multiple sclerosis
por: Aldughmi, Mayis, et al.
Publicado: (2016)

Visual consequences of medications for multiple sclerosis: the good, the bad, the ugly, and the unknown
por: Moss, Heather E
Publicado: (2017)

Immunological Consequences of In Utero Exposure to Foreign Antigens
por: Chen, Jeng-Chang
Publicado: (2021)

Immunological consequences of arsenic trioxide-induced necrosis
por: Gavali, Shubhangi, et al.
Publicado: (2023)

Sleep Disturbance and Immunological Consequences of COVID-19
por: Bocek, Jonas, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_kqs45mud8okqi6qle6rpgt0t4m